EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER‐ALZ 2 trial

Lars L Raket iD, Ming Lu, Cynthia D Evans, Jennifer A Zimmer, JonDavid Sparks, Emily C Collins, Sergey Shcherbinin, Hong Wang, Emel Serap Monkul Nery, Stéphane Epelbaum, Grazia Dell'Agnello, Dawn A Brooks und 2 weitere

Alzheimer's & Dementia · 2026

DOI: 10.1002/alz.71577 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Alzheimer's & Dementia, 2026. Verfasst von Lars L Raket und 13 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, tau Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Clinical trials indicate that disease‐modifying therapies can slow clinical decline in Alzheimer's disease (AD), with earlier initiation associated with greater slowing. METHODS In the TRAILBLAZER‐ALZ 2 trial, the treatment effect of donanemab on the Clinical Dementia Rating Scale Sum of Boxes (CDR‐SB) score was assessed across disease stages defined by baseline tau PET, plasma P‐tau217 levels, or predicted disease progression. RESULTS Donanemab‐mediated slowing of disease progression occurred across baseline tau PET and plasma P‐tau217 levels. Participants with lower baseline tau PET and P‐tau217 showed greater slowing with donanemab versus placebo. Modeling CDR‐SB scores indicated that earlier treatment (at the 25 th percentile of baseline Predicted disease progression) delayed disease progression by 60% over 76 weeks, compared to 33% and 17% at the 50 th and 75 th percentiles. DISCUSSION Donanemab benefited participants with early symptomatic AD across clinical and pathological severities, with the greatest slowing in those treated earlier. ClinicalTrials.gov Identifier: NCT04437511

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer Diseasetau ProteinsAgedFemaleHumansMaleDisease ProgressionDouble-Blind MethodPositron-Emission TomographySeverity of Illness IndexTreatment OutcomeAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Alzheimer's diseaseP‐tau217amyloid‐targeting therapydisease progression modelingneurodegenerationtau PET

Substanzen

donanemabtau ProteinsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Eli Lilly and Company, Indianapolis, Indiana, USA.

ORCID-Profile: Lars L Raket

Förderung

  • Eli Lilly and Company

Zitieren

APA

Raket, L. L., Lu, M., Evans, C. D., Zimmer, J. A., Sparks, J., Collins, E. C., Shcherbinin, S., Wang, H., Nery, E. S. M., Epelbaum, S., Dell'Agnello, G., Brooks, D. A., Sims, J. R., & Mintun, M. A. (2026). Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER‐ALZ 2 trial. Alzheimer's & Dementia. https://doi.org/10.1002/alz.71577

Vancouver

Raket LL, Lu M, Evans CD, Zimmer JA, Sparks J, Collins EC, et al. Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER‐ALZ 2 trial. Alzheimer's & Dementia. 2026. doi:10.1002/alz.71577

BibTeX
@article{Raket2026,
  author = {Raket, Lars L and Lu, Ming and Evans, Cynthia D and Zimmer, Jennifer A and Sparks, JonDavid and Collins, Emily C and Shcherbinin, Sergey and Wang, Hong and Nery, Emel Serap Monkul and Epelbaum, Stéphane and Dell'Agnello, Grazia and Brooks, Dawn A and Sims, John R and Mintun, Mark A},
  title = {Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER‐ALZ 2 trial},
  journal = {Alzheimer's & Dementia},
  year = {2026},
  doi = {10.1002/alz.71577}
}
Kostenlos starten →